Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), H. Kabitz (Konstanz , Germany), L. Hagmeyer (Solingen, Germany), P. Hammerl (Immenhausen, Germany), A. Esselmann (Warendorf, Germany), C. Wiederhold (Fulda, Germany), D. Skowasch (Bonn, Germany), C. Stolpe (Ibbenbüren, Germany), M. Joest (Bonn, Germany), S. Veitshans (Böblingen, Germany), S. Witt (Munich, Germany), R. Leidl (Munich, Germany), A. Hellmann (Augsburg , Germany), M. Pfeifer (Donaustauf, Germany), J. Behr (Munich, Germany), A. Guenther (Gießen, Germany), D. Kauschka (Essen, Germany), F. Herth (Heidelberg, Germany), P. Markart (Fulda, Germany). Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry. 2197

Member's Comments

No comment yet.

Related content which might interest you: Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD) Source: Eur Respir J 2004; 24: Suppl. 48, 533s Year: 2004 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases Year: 2012 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study Source: Annual Congress 2006 - Quality of life in various respiratory diseases Year: 2006 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 COVID-19: Current Challenges in ILD Source: ERS webinar 2020: COVID-19: Current Challenges in ILD Year: 2020 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 The similarity and difference of pathology of pulmonary arterioles in COPD and idiopathic lung fibrosis (IPF) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010